7 月 3 日,NMPA 官网显示,恒瑞医药引进的全氟己基辛烷“SHR8058 滴眼液”获批上市,用于治疗睑板腺功能障碍(MGD)相关干眼病。该药物为恒瑞2019年11月从德国Novaliq公司引进,恒瑞将获得这两个产品在中国的临床开发、生产和市场销售的独家权利。| 防止泪膜蒸发,缓解眼睛干涩疼痛睑板腺功能障碍(MGD)是一种慢性、弥漫性睑板腺功能异常,可导致泪膜改变、泪膜稳定性降低和眼刺激症状。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.